Plasma concentrations of clonazepam after single rectal administration

G W RYLANCE, J POULTON, R C CHERRY, AND R E CULLEN

Children’s Hospital, Birmingham

SUMMARY Clonazepam was administered rectally to six children aged 1·4 to 4·7 years in a dose of 0·05 mg/kg and to five children aged 1·4 to 4·1 years in a dose of 0·1 mg/kg. Plasma concentrations indicate that it is rapidly absorbed, and it may therefore be an alternative to rectal administration of diazepam in continuing convulsions.

Diazepam is considered to be the drug of choice for continuing convulsions. Used rectally, it is a safe and rapidly effective treatment that can be administered easily and conveniently by paediatric residents, general practitioners, nurses, and parents.

It may, however, cause respiratory depression, and convulsions sometimes recur after initial suppression.

Intravenously administered clonazepam is effective in all forms of continuing convulsions and has a longer duration of action than diazepam. Respiratory depression seems to occur much less commonly than with diazepam. Blood concentrations after rectal administration in adults are similar to those achieved after intravenous administration, but the rate and extent of absorption of rectally administered clonazepam in children is not known.

We have determined the plasma concentration time profiles after rectal administration of two different doses.

Methods

Eleven children (nine boys and two girls) were included in the study. Their ages ranged from 1·4 to 4·7 years (Table). They were all in good general health but had previously had convulsions associated with fever. One child was taking sodium valproate and another carbamazepine regularly. The test doses were given to confirm adequacy of absorption and suitability for individual home use. Ethical approval from the local district research ethical committee had been obtained.

The commercial appropriately diluted intravenous preparation Rivotril (Roche, UK) was administered directly into the rectum through 1 ml

Table

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age (yrs)</th>
<th>Other drugs</th>
<th>Dose (mg/kg)</th>
<th>Time after administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>4·6</td>
<td></td>
<td>0·044</td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>4·7</td>
<td></td>
<td>0·046</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>4·6</td>
<td></td>
<td>0·050</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>1·4</td>
<td></td>
<td>0·050</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>2·3</td>
<td>Carbamazepine</td>
<td>0·040</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>1·4</td>
<td></td>
<td>0·050</td>
<td>—</td>
</tr>
<tr>
<td>7</td>
<td>2·0</td>
<td></td>
<td>0·091</td>
<td>—</td>
</tr>
<tr>
<td>8</td>
<td>3·3</td>
<td></td>
<td>0·099</td>
<td>—</td>
</tr>
<tr>
<td>9</td>
<td>1·4</td>
<td></td>
<td>0·095</td>
<td>—</td>
</tr>
<tr>
<td>10</td>
<td>3·1</td>
<td>Sodium valproate</td>
<td>0·100</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>4·1</td>
<td></td>
<td>0·100</td>
<td>—</td>
</tr>
</tbody>
</table>

*Undetectable concentration.

Table Plasma clonazepam concentration in 11 children after single rectal dose administration (ng/ml)
Results

The Table shows the clonazepam concentrations for each dose. One child (case 1) in the group given 0.05 mg/kg did not achieve detectable concentrations. Two others (cases 2 and 3) failed to achieve concentrations above the lower limit for detection in the group given 0.1 mg/kg. The 10 minute concentration in case 8 was disproportionately high and out of line with the remaining profile. It has been omitted from the following results. Peak concentrations in children given 0.05 mg/kg ranged from 2.8 to 12.0 ng/ml and occurred 20–60 minutes after rectal administration. Peaks of 18.4–40.5 ng/ml occurred between 10 minutes and two hours in those given 0.1 mg/kg. No child in either dosage group had detectable concentrations before seven minutes.

The Figure shows the mean (SE) concentration time curve for children given 0.1 mg/kg.

All children given 0.1 mg/kg became drowsy, fell asleep within 20 minutes, and remained so for over three hours. Three (cases 8, 10, and 11) remained ataxic and incoordinated at four hours.

Discussion

Peak concentrations between 10 minutes and two hours after rectal administration of solution suggest that clonazepam is rapidly absorbed from the rectum. These concentrations occurred slightly later, however, than those reported for diazepam in children. Peak concentration times after intravenous injection have not been reported in children of this age, but it must be assumed that the peaks after rectal administration occur later.

Blood concentrations of clonazepam necessary to stop continuing convulsions are not known. Ståhl et al reported that epileptogenic discharges on electroencephalogram were noticeably reduced or abolished for varying periods in four children given clonazepam intravenously; peak concentrations at these times ranged from 7 to 11 ng/ml. Congdon and Forsythe found no recurrence of convulsions in children with concentrations above 17.7 ng/ml. In adults clonazepam concentrations up to 36.8 ng/ml were obtained in volunteers given 2 mg intravenously. This dose is twice that which usually stops convulsions in this age group. A therapeutic concentration threshold of 18 mg/ml might therefore be suggested, although this may be higher than necessary and subject to wide interindividual variation.

No child given 0.05 mg/kg achieved this concentration, but the value was exceeded within 20 minutes in all children given the higher dose. Slightly lower concentrations achieved by all children within 10 minutes may well be effective.

None of the children in this study showed signs of respiratory depression. This has been reported considerably more often after the use of diazepam intravenously, although this may reflect the more common use of this drug. Other adverse effects did occur, however, in all children in the higher dosage group. They had muscular incoordination, ataxia, and sleepiness with onset within 20 minutes of administration and a duration of at least three hours. The three patients who remained ataxic at four hours were not one hour later, although all remained drowsy. Although these effects occurred when plasma concentrations were highest and were only present when concentrations exceeded 18 ng/ml, except in case 11 who was not ataxic with a concentration of 20.2 ng/ml at 12 hours, there may be no clear relation between such adverse effects...
and drug concentrations. Similar concentrations produced such effects in only half the children in the series reported by Dreifuss et al. 13 Whether the incidence of such effects after the use of clonazepam to stop convulsions represents a major disadvantage is not clear.

If clonazepam is the drug of choice for continuing convulsions 14 then the facility for a convenient and rapidly effective therapeutic approach offered by rectal administration would be as important for clonazepam as has been shown to be the case in practice for diazepam. These results suggest that a dose of 0.1 mg/kg clonazepam administered rectally to young children may be expected to produce a rapidly effective anticonvulsant effect. Further work is necessary to confirm its rapid absorption, its usefulness as an effective treatment, and to develop convenient means of administration along lines presently offered by the availability of rectal tubes containing diazepam (Stesolid).

R E Cullen is a research nurse supported by a grant from the Birmingham Children's Hospital Centenary Research Fund. We thank Roche Products Limited for undertaking the drug assays.

References


Correspondence to Dr G W Rylance, Children's Hospital, Ladywood Middleway, Birmingham B16 8ET.

Received 28 October 1985
Plasma concentrations of clonazepam after single rectal administration.
G W Rylance, J Poulton, R C Cherry and R E Cullen

Arch Dis Child 1986 61: 186-188
doi: 10.1136/adc.61.2.186

Updated information and services can be found at:
http://adc.bmj.com/content/61/2/186

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/